Location History:
- Ruhstorf a.d. Rott, DE (2011)
- Princeton, NJ (US) (2013 - 2016)
Company Filing History:
Years Active: 2011-2016
Title: The Innovative Contributions of Inventor Peter Riebel
Introduction
Peter Riebel is a distinguished inventor based in Princeton, NJ, recognized for his contributions to the pharmaceutical field. With three patents to his name, Riebel has been at the forefront of developing critical compounds aimed at improving health outcomes, particularly in the treatment of diseases such as diabetes.
Latest Patents
Riebel's latest patent involves the crystal structures of SGLT2 inhibitors and processes for preparing the same. This innovation relates to the physical crystal structures of compounds that hold significant potential in pharmaceutical compositions. The compounds, as defined in his patent, include intermediates used in preparing these compounds and methods for treating diseases like diabetes. The detailed technical specifications of these inventions highlight their importance in advancing therapeutic strategies for managing health conditions.
Career Highlights
Throughout his career, Riebel has worked with prominent pharmaceutical companies, including Bristol-Myers Squibb Company and AstraZeneca AB. His experience in these industry leaders has undoubtedly contributed to his success as an inventor and helped in refining his skills in drug development.
Collaborations
Peter Riebel has collaborated with notable colleagues such as Jack Z Gougoutas and Hildegard Lobinger. These professional relationships have allowed for the exchange of ideas and insights, which are crucial in the innovative process of developing new pharmaceutical compounds.
Conclusion
In summary, Peter Riebel's work exemplifies the impact of innovation in the pharmaceutical industry. With his latest patents revolving around SGLT2 inhibitors, he continues to make strides in improving treatment options for diabetes and potentially other related health issues. Riebel's career and collaborations reflect the essence of teamwork and dedication to advancing medical science.